Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Didanosine EC Triple Combination vs Reference in HIV
NCT00002429Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 1999
- Primary completion
- Jan 2001
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of didanosine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Proportion of patients with HIV RNA levels of less than 400 copies/ml at 48 weeks. Started Jul 1999; status: completed.
02
Drugs
didanosine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00002429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002429.